Noseguard for Prevention of Respiratory Infections in Real-World Use
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19+
SponsorDaewoong Pharmaceutical Co. LTD.
About this trial
This study is a prospective clinical study to evaluate the effectiveness of combined use of two nasal protective medical devices (Noseguard and Noseguard Night) in reducing respiratory infection rates, including COVID-19 and influenza, in real-world conditions.
The study will also assess usability, satisfaction, and safety using electronic patient-reported outcomes (ePRO).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged ≥19 years
Able to provide informed consent
Disqualifiers
Hypersensitivity to device components
Current COVID-19 or influenza infection
Severe nasal disease
Pregnant or breastfeeding women
Trial design
Design model
Single group
Treatments tested in this trial
Noseguard and Noseguard Night
DeviceNasal spray medical devices used to form a protective barrier on the nasal mucosa to reduce viral entry.
Treatment groups
2,000 Participants
are divided into 1 treatment groupGroup A: Noseguard Combined UseExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Incidence of Respiratory Infection
Incidence of respiratory infections, including COVID-19 and influenza, during the 8-week study period.
Time frame
Week 8Secondary outcomes
1
Incidence of Respiratory Infection by Interval
Incidence of respiratory infection during each interval
Time frame
Up to Week 8Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: